Uremia
Conditions
Interventions
Control group:The control group was given conventional treatments such as blood pressure control, optimization and stabilization of hemoglobin levels, reduction of volume load, and correction of calci
Amrisentan treatment group:The experimental group was given amrisentan treatment (oral administration, 5mg, once a day) on the basis of conventional treatment.
Sponsors
The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed with uremia, the diagnostic criteria met the diagnostic criteria of the "2023 KDIGO-CKD Evaluation and Management Clinical Practice Guidelines", and maintenance hemodialysis was performed for at least 3 months; (2) PASP was detected and calculated by color Doppler echocardiography, with PASP > 35mmHg; (3) The symptoms of PAH are WHO grade II or grade I symptoms; (4) Had never taken targeted drugs related to the treatment of PAH before enrollment; (5) The patient agrees to the treatment and signs the relevant informed consent form, and the patient can understand the research process; (6) Aged between 18 and 80;
Exclusion criteria
Exclusion criteria: (1) PAH is related to arterial or left heart disease, or pulmonary hypertension is caused by chronic thromboembolism; (2) Patients who are allergic to amrisentan or have contraindications for its use; (3) The patient participates in any other research and conducts research and/or receives or has received another research drug or intervention treatment (within the first month before signing the informed consent form); (4) Moderate to severe or severe liver disease (AST and ALT>) 2.5 times the upper limit range and total bilirubin 1.5 times the upper limit range; (5) The individual or legal guardian/representative is unable or unwilling to provide a written informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of hospitalization due to aggravated pulmonary arterial hypertension;Pulmonary Arterial Systolic Pressure, PASP; | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP;WHO Respiratory Function assessment; | — |
Countries
China
Contacts
Public Contactxiong jiachuan
The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Outcome results
None listed